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Abstract
The WHO Malaria Vaccine Advisory Committee (MALVAC) provides advice to WHO on strategic priorities, activities
and technical issues related to global efforts to develop vaccines against malaria. MALVAC convened a series of
meetings to obtain expert, impartial consensus views on the priorities and best practice for vaccine-related research
and development strategies. The technical areas covered during these consultations included: guidance on clinical
trial design for candidate sporozoite and asexual blood stage vaccines; measures of efficacy of malaria vaccines in
Phase IIb and Phase III trials; standardization of immunoassays; the challenges of developing assays and designing
trials for interventions against malaria transmission; modelling impact of anti-malarial interventions; whole organism
malaria vaccines, and Plasmodium vivax vaccine-related research and evaluation. These informed discussions and
opinions are summarized here to provide guidance on harmonization of strategies to help ensure high standards of
practice and comparability between centres and the outcome of vaccine trials.
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Background
Much has been achieved in controlling malaria in many
endemic areas of the world [1,2] and further progress is
possible through universal access to and use of existing
malaria preventive, diagnostic and treatment measures,
including transmission reduction through Anopheles
mosquito vector control. Nevertheless, current tools on
their own are unlikely to provide elimination in areas of
highest transmission, especially in Africa, and new tools
are needed. One or more effective vaccines which can
be added to available measures could fill that critical
gap and could support malaria control. Despite some
investment in research on the development of malaria
vaccines over the past thirty years [3,4], currently only
one candidate vaccine, RTS,S/AS01, has reached the
stage of phase III clinical trials, with the prospect of be-
ing submitted for consideration of licensure soon [5]; sev-
eral others have been tested in phase II field trials [6].
Throughout this period of increased vaccine effort,
WHO has had an important role in supporting various
aspects of basic research projects through the WHO/
UNDP/World Bank Special Programme (WHO/TDR)
and has also played a major normative role in providing
guidance on many aspects of vaccine development.
Landmark meetings were held to highlight the need for
improved adjuvants, by bringing together representa-
tives of groups involved in developing and testing new
potential products, recognizing that malaria antigens
were often involved in the first wave of testing novel
agents [7]. WHO worked with funding agencies to con-
vene meetings of scientists, regulators and others to re-
view the state of the art of vaccine development,
reviews of key ethical issues [8], and maintains an on-
going record of malaria vaccines under development
(known as the Rainbow Table) [3]. Perhaps most im-
portantly, WHO has worked with its advisory commit-
tees to gather best evidence then provide guidance for
vaccine trial designs that ensure that results generated
are relevant for establishing subsequent policy recom-
mendations, to assist national programmes in malaria-
endemic countries.
WHO’s advisory committees are a key mechanism for
identification of research priorities for immunization and
for development of consensus-based guidance on clinical
development and testing of vaccines. The WHO Malaria
Vaccine Advisory Committee (MALVAC) succeeded
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IMMAL and VDR Committees, and provides advice to
WHO on strategic priorities, activities and technical
issues related to global efforts to develop vaccines
against malaria, with emphasis on the public health
needs of developing countries. In the five years 2008–
2013 MALVAC has convened eight key meetings of
experts, together with several working groups, whose
detailed assessments have provided valuable consen-
sus views on priorities and best practice for selected
vaccine-related research and development strategies.
By providing the leading independent global malaria
vaccine forum for funding agencies, sponsors and in-
vestigators, WHO has increased collaboration between
key malaria vaccine R&D stakeholders. WHO has also
improved the comparability of key endpoints by con-
vening technical groups to provide consensus based
protocols and Standard Operating Procedures, ensur-
ing extensive consultation amongst stakeholder
groups. The technical areas for these consultations
have included design and conduct of sporozoite chal-
lenge trials, Standard Operating Procedures for mal-
aria microscopy in challenge trials, [9] optimization of
clinical challenge trials for asexual blood stage vac-
cines, measures of efficacy of malaria vaccines in
phase IIb and phase III trials, workshops on stan-
dardization of malaria vaccine immunoassays, evalu-
ation of assays and trial designs to be applied to
interventions against malaria transmission, develop-
ment of whole organism vaccines for malaria endemic
countries, and priorities in research and development of
vaccines for Plasmodium vivax and their evaluation.
Recently, WHO highlighted the need for information-
sharing among HIV, TB and malaria vaccine communities
and working with NIAID convened a technical forum on
heterologous prime-boost immunization across the three
diseases [10]. Furthermore the MALVAC committee will
have a key role in advising WHO on the updated version
of the Malaria Vaccine Technology Roadmap [11].
These informed and impartial opinions and recom-
mendations are summarized here to provide guidance
on harmonization of strategies that will help to ensure
high standards of practice, and comparability between
centres and the outcome of vaccine trials. Reference is
made to reports of the meetings (and to selected other
relevant publications) that provide the more detailed dis-
cussions on which the recommendations are based. The
text below summarizes the reports of individual meetings
and should not be considered to be the position or policy
of the WHO. For outcomes of individual meetings, rea-
ders are directed to the individual meeting reports.
There is a distinct WHO advisory mechanism which
provides advice on vaccine candidates in advanced develop-
ment and approaching possible availability for use. This is
known as the Joint Technical Expert Group (JTEG) on
malaria vaccines, reporting jointly to the WHO Strategic
Advisory Group of Experts on Immunization, and to
WHO’s Malaria Policy Advisory Committee [12]. MALVAC
will continue to provide advice to WHO on the longer term
malaria vaccine R&D considerations, with JTEG available
to provide evidence reviews for possible policy recommen-
dations when products become sufficiently advanced.
Consensus-based guidance on clinical trial design
A vital part of the development of candidate malaria
vaccines is the careful planning of all phases of clinical
trials, always with a view to enhancing comparability be-
tween vaccine clinical trials, sites, and alternative devel-
opment programmes. A second important objective is
generation of data to terminate or advance projects ap-
propriately. Phase I trials are used to determine whether
candidate vaccines have the required profile of safety
and immunogenicity, with Phase IIa trials in malaria
designed to provide actionable information on efficacy,
safety and immunogenicity including controlled human
malaria infection. They are screening trials intended to
select candidate vaccines to take forward into field trials,
and to select which vaccine formulations to terminate.
These proof of concept studies have usually started with
adults in non-endemic areas before moving to the target
group of children of an endemic area. Phase IIb and III
proof of principle field trials require progressively larger
numbers of subjects depending on the primary endpoint
to be measured and the controls necessary for compari-
son. Phase III trials are traditionally designed with the
primary objective of providing data suitable for regula-
tory filing. However a focus in malaria vaccines has been
to ensure that data are also suitable for evidence-based
public health policy recommendations as far as possible.
This can avoid the need for additional Phase III trials.
Challenge trials in malaria-naïve volunteers
Sporozoite challenge trials for pre-erythrocytic and
blood-stage vaccines
Controlled Human Malaria Infections (CHMI) [9,13] are
used to assess candidate vaccine efficacy in malaria-naive
individuals. Challenge trials in volunteers are important as
they inform future clinical trials – whether or not to
proceed; dosing, route, schedule and vaccine presentation.
This allows iterative improvement of the vaccine construct
and its use. Field trials for pre-erythrocytic vaccines should
be dependent on first achieving a pre-determined level of
efficacy in challenge trials. Future efficacy field trials of
new vaccine candidates or combinations may well have to
be non-inferiority trials (if RTS,S, for example, is licensed)
in regions of reduced transmission, potentially requiring
very large sample sizes, thus making them costly and com-
plex with subjects enrolled in several centres. The need to
achieve greater confidence in expectations of efficacy prior
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to initiating multi-million dollar field studies in large
numbers of individuals means that even greater reliance
may be placed on carefully standardized CHMI studies.
They will also be important for the same reasons in go/no
go criteria and prioritization of blood stage vaccines
(Figure 1). The significant additional challenges with
P. vivax challenge trials are considered later.
Blood stage challenge trials
As an alternative to sporozoites, parasitized erythrocytes
can be used to challenge vaccinated individuals [14].
They may have advantages over sporozoite challenge for
testing the efficacy of blood-stage vaccines since they
allow use of a standardized and low dose challenge and,
consequently, a longer period for assessment of induced
Screening of potential participants 
A pre-requisite is very careful selection of potential volunteers involving extensive health screening, 
including mental health and specific infections, disorders, or concurrent treatments that could compromise 
the outcome of the trials.  
The safety of the volunteers must be paramount throughout the study and they must be fully informed about 
the nature of the trial and kept up to date with its progress as it affects them.
Parasite and mosquito strains 
The recommended procedure includes use of a Plasmodium falciparum malaria isolate, or one of its clones, 
that is adapted to culture.  All must have defined sensitivities to effective drug treatments, and blood donors 
for parasite culture need screening for known infectious agents.  Banks of parasites are available.  
Laboratory bred anopheline mosquitoes have been used.  Safety procedures are again the highest priority. 
Infectivity controls and challenge 
A control (non-vaccinated) group of volunteers should be included.  All volunteers are exposed to a fixed 
number of infected mosquitoes (five) for a defined period of time within totally secure insectaries. For 
efficacy analysis, trial size is greatly impaired if even one of the control subjects does not develop patent 
parasitaemia, hence a large dose is given which may represent an unnaturally high (artificial) challenge. 
Recently, mass-produced purified, GMP standard cryopreserved sporozoites have been assessed for human 
challenge trials[13].  
Follow-up 
A precise schedule of follow-up is required to cover the period of possible acute allergic reactions or other 
adverse events, and the onset of malaria infections that require prompt optimal treatment.  
Formal outreach plans are required in the event that a volunteer does not attend for follow-up prior to 
receiving curative treatment. 
Endpoints 
The primary endpoint is first detection of patent parasitaemia, usually as determined by microscopy, 
measuring parasites per unit volume in thick blood films. Fully developed and agreed standard operating 
procedures (SOP) that take account of local variations in procedure but give a standardized outcome 
measure have been developed[9]. The expertise required by clinical trial microscopists is distinct from 
that needed for diagnosis in malaria-endemic regions, since the requirement is to be able to detect the 
earliest stage of patency, whilst avoiding false positives. 
A secondary endpoint is the pre-patent period, the time interval between challenge and the first occurrence 
of patent parasitaemia, which can vary depending on both parasite and host characteristics. 
Increased frequency of blood sampling (e.g. twice daily), in order to measure accurately peripheral blood 
parasite density and pick up even modest efficacy, particularly in blood stage vaccine trials, should be 
employed. 
Molecular detection methods (PCR) are an important supplement to blood film diagnosis, and may replace
microscopy as the standard in some centres in the future. These molecular genetic techniques allow more 
precise calculation of growth rate, and have decreased the detection threshold for asexual parasitaemia 
substantially. Harmonization of PCR methods is needed to ensure comparability, and the establishment of a 
reference centre and repository may be beneficial. 
Evaluation of parasite growth curves can be helpful for assessment of efficacy that relates to reduction in 
numbers of parasites leaving the liver.  
Immune correlates of protection are not yet fully defined. CHMI allows these to be explored and 
opportunities should be taken to do so. 
Figure 1 Standardization and conduct of P. falciparum sporozoite controlled human malaria infection trials. CHMI is used to denote
sporozoite challenge but it is also sometimes used too for blood-stage challenge.
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blood stage immunity before parasites are detected and
treatment is required. In contrast, the large sporozoite
challenge required to ensure that every control subject is
infected may lead to heavy infection and a large num-
bers of parasites leaving the liver and, as a consequence,
earlier detection of parasites requiring treatment.
Rigorous safety depends on having a well-characterized
source of erythrocytes free from adventitious agents that
meet stringent blood product safety requirements. This is
the area of particular concern that for some investigators
may still outweigh the perceived benefits of blood-stage
challenge. The antigenicity of infected red blood cells in
vaccinated volunteers is also a safety issue to be consid-
ered. Quantitative PCR monitoring of infection is valuable
as it provides a detection threshold of asexual parasitaemia
of approximately 20 parasites/ml, well below that possible
by microscopy, and potentially increases the time for ob-
servations and assessment of efficacy before treatment is
required.
There are, however, some drawbacks to use of blood-
stage challenge. The challenge bypasses skin and liver
stages of infection and removes the possibility of de-
tecting protective cellular immune responses against the
late liver stage or antibody against merozoites released
from the liver. A low inoculation of parasitized erythro-
cytes has no counterpart in naturally acquired blood
stage infection. Further development of blood stage chal-
lenge trials and comparisons with sporozoite challenge are
desirable. Development of multiple antigenically distinct
parasite strains for evaluation of heterologous protection
is also required. Independent evaluation of methods used
for modelling parasite growth curves should be made to
assist decision-making.
Phase IIb and Phase III malaria vaccine trials
Detailed recommendations were made on the implica-
tions of different measures of efficacy as they affect vac-
cine impact, comparability of trials, licensure and wider
public health benefits [15]. The conclusions were:
 Field evaluation of a vaccine has to be done in the
context of other control measures. Assessing efficacy
is complicated for malaria where first infection
(or vaccination) gives only partial protection against
re-infection and the same individual may have
multiple episodes of clinical malaria. The primary
measure of efficacy is commonly reported as the
incidence of first episode of infection or of clinical
malaria. This takes no account of subsequent
episodes and, from a public health perspective,
reduction in the total number of events in some
defined time period following vaccination is more
relevant than measuring time to first event as the
primary efficacy endpoint.
 Incident malaria infection is a prerequisite of clinical
malaria but, additionally, there can be incident
infections without clinical symptoms. If protection
against incident malaria infection could be used as a
correlate for protection against clinical malaria,
this would allow smaller trial sizes and less cost
(in malarious areas where many trials are likely to be
conducted, incidence of infection is high, with the
vast majority of susceptible individuals expected to
experience infection in a one to three month period
at the peak of local transmission).
 A high incidence of malaria and heterogeneity of
exposure make estimates of efficacy difficult. In
particular, waning of efficacy and heterogeneity in
exposure cannot be distinguished by measuring the
proportion of individuals remaining disease free at
different times after vaccination. Boosting from
natural infection should be evaluated. Trial designs
in endemic countries will need to be able to detect
duration of protection at least up to two years after
vaccination, and to rule out deferred or rebound
increases in mortality as a consequence of increasing
susceptibility following a period of vaccine-induced
immunity.
 Evaluation of efficacy in the context of existing
malaria preventative interventions is a priority.
The dosing schedules required for successful
vaccination may have implications for feasibility of
scale-up. Possible interference with EPI vaccines in
infants should be assessed. The possibility of
reduced transmission in some field trial sites will
need to be addressed in field trial design; larger
enrolments may be required, and because age at risk
will have extended beyond the ages for EPI, vaccines
may also need to be administered to the older
children at risk.
 Safety, immunogenicity and efficacy should be
established prior to a vaccine being given to specific
high risk groups (e.g. infants, in pregnancy, and
immune-compromised individuals), Monitoring and
evaluation plans should include both
pharmacovigilance and a sustainable disease burden
monitoring system. However these pose major
challenges in many malaria-endemic settings.
 Impact on malarial transmission (see below) is a key
part of assessment of any potential new malaria
intervention, although it may not be included in the
first Phase III trial. The future combination of single
or multi-component candidate malaria vaccines with
other malarial interventions should be considered.
 As a general rule methods for design and analysis of
Phase III trials should be registered in publicly
available data bases before results are unblinded.
Data sharing will increase understanding of the
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likely public health impact of a new vaccine in the
context of existing control measures.
 Post-licensure, data should be acquired on
long-term effectiveness in multiple transmission
settings and changing control measures and
epidemiology, noting the consequences when
immune individuals have long periods of reduced
exposure, for example whether they become more
susceptible to the consequences of later episodes of
malaria. The long-term safety must also be
evaluated.
Measures of efficacy of interventions against malaria
transmission
Reduction in transmission remains the fundamental goal
of malaria control and measuring changes in transmis-
sion allows a better understanding of the interactions
between different interventions (vector control, treat-
ment, vaccination) and their combined impact. Some
currently available anti-malarial interventions lead to a
reduction in transmission even in highly malarious areas,
and transmission reduction is the key metric in a malaria
elimination strategy.
Better measures of transmission are needed but, as
yet, there are no agreed and standardized measures of
malaria transmission and these may need to be different
in areas of high and low transmission. Measurement of
transmission is costly and time-consuming, requiring
repeated observations. In some very low transmission
areas, incident infection leads to disease and may, there-
fore, be a surrogate for ongoing transmission. However,
in other areas of very low transmission, substantial num-
bers of asymptomatic infections have been detected with
sensitive molecular tools. At low transmission intensity
(for example in some of the environments in which
transmission blocking vaccines are likely to be tested and
introduced) estimates have very large confidence intervals
and surrogates are required (see below). Transmission
blocking vaccines (TBV) specifically target sexual or spo-
rogonic stage parasites, or mosquito midgut antigens.
However, the so-called vaccines that interrupt malaria
transmission (VIMT) may have their primary effect on
other of the three main life-cycle stages but, additionally,
may have a significant indirect effect on transmission.
The key effect required for sexual stage or mosquito
antigen targets is substantial reduction in the proportion
of infected mosquitoes. By contrast, the key effect re-
quired for pre-erythrocytic vaccines when viewed as
VIMT, is a major reduction in the proportion of humans
carrying sexual stages.
A WHO MALVAC meeting considered measures of ef-
ficacy of anti-malarial interventions against malaria trans-
mission [16]. The objectives were to evaluate current
methods for measurement of malaria transmission and
assessment of assays and clinical trial designs that should
be applied to measurement of reduction of transmission
(of Plasmodium falciparum). The measures considered
necessary included:
(i) Epidemiological (incidence of new infections)
(ii) Standardized assays of transmission from humans
to mosquitoes (Figure 2) [16,17]
(iii)Entomological (estimating new human infections by
mosquito measures)
(iv) Surrogate serological and molecular measures, e.g.
sero-negativity in young children as transmission
declines.
A major gap in knowledge is the lack of understanding
of the relationship between a result in a trial in a group
of vaccinated individuals (each one having a different
percentage reduction in oocysts in a different percentage
of mosquitoes fed on that person), and the potential
effect on transmission. It may be that the most import-
ant figure is the proportion of vaccinated individuals
who are rendered unable to be a source for feeding
mosquitoes to become infectious; another parameter
may be the duration of infectiousness of vaccinees.
Heterogeneity in malaria transmission and focal
transmission (hotspots)
There is spatial and temporal heterogeneity in malaria
transmission in both low and high transmission endemic
areas, seen particularly in incidence of infection in infants
and in population based sero-positivity rates. High-density
carriers of gametocytes transmit more often in feeding
experiments but, importantly, sub-microscopic gameto-
cyte carriers may account for a substantial proportion of
transmission. Molecular techniques are required for detec-
tion of sub-patent infections as microscopy and rapid diag-
nostic tests (RDT) miss many asexual blood stage parasites
and gametocytes. Targeting young children alone with
transmission-reducing interventions is unlikely to be suc-
cessful, as older children and adults also infect mosquitoes.
Entomological measures of transmission
The two key measures used to evaluate the impact of
interventions are the entomological inoculation rate
(EIR), the number of infectious bites per person per unit
of time (day, year), and the daily rate of potential trans-
mission by a mosquito population known as the vector-
ial capacity. Human landing catches (HLC) are used as
the standard for mosquito collection but subjects vary in
their attractiveness and there are ethical concerns. Light
traps are used as an alternative and to compare indoor/
outdoor biting and time of biting. They lack reliability
outdoors and the mosquito composition may vary from
HLC.
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The minimum EIR measureable reliably is 5–10 and
transmission-blocking vaccine trials are likely to be
conducted at field sites with low to moderate EIR. Non-
random distribution of vectors, as well as endophilic or
exophilic behaviour, present problems. Serological mea-
sures of exposure of humans to Anopheles salivary pep-
tides can be used to measure changes such as the
impact of ITNs on biting. ELISA measures of sporozoite
infections in mosquitoes are convenient but some re-
ports have indicated a high level of false positivity which
gives an overestimate of infected mosquito rates. Meas-
uring the infection rate according to age in wild caught
mosquitoes requires labour intensive age grading and
large numbers of mosquitoes.
Clinical trials of transmission-blocking vaccines
Phase Ia, Ib and IIb vaccine studies
Safety and immunogenicity and functional activity will
be required, as already indicated, before progression
from Phase I in naïve volunteers to endemic country
trials. Intermediate proof of principle may be shown by
demonstrating antibody-mediated reduction in infectiv-
ity of humans to mosquitoes in membrane-feeding
assays. Efforts to validate or quantify the assays are
required and, currently, Go/No-go criteria from Phase I
to Phase IIb trials are not agreed. The possibility of
demonstrating a reduction in infectivity of vaccinated
humans to mosquitoes in Phase IIb also needs further
standardization of study design and analysis.
Phase III design for a malaria TBV
Field trial sites for phase III trials need to be character-
ized in terms of parasite prevalence and heterogeneity
(hotspots), infectious reservoirs, incidence of infection
or clinical malaria in infants; mosquito exposure; ser-
ology and natural transmission-blocking immunity.
There are challenges for design of clinical trials in both
high and low transmission sites as an effect may be diffi-
cult to show in one case, and power may be lacking to
show an effect in the other. Furthermore, transmission
may change over the several years of the study. Trial
design will be complex. Cluster-randomized efficacy
trials may be required, and a step-wedge design has also
been suggested.
It is important to distinguish between those interven-
tions with expected direct effects on other stages of the
life cycle and possible indirect effects on transmission
(VIMT), and interventions only expected to have effects
1. Direct feeding assay (DFA) 
Laboratory reared mosquitoes are fed on naturally exposed individuals. 
Some ethical committees have expressed concerns about DFA especially when children are involved, others 
continue to approve use of DFA in adults. 
2 Direct membrane-feeding assay (DMFA) 
Blood samples drawn from naturally infected humans are used for membrane feeding of mosquitoes. 
An advantage is it provides assessment of field derived parasite isolates. 
Control results (a measure of inherent infectivity) are determined by replacing autologous plasma with non-
immune serum prior to feeding. 
The assay is difficult to standardize 
3 Standard membrane feeding assay (SMFA) 
Uses sera or purified immunoglobulins, in vitro cultured gametocytes, and laboratory strains of Anopheles 
mosquitoes. 
It is valuable for both pre-clinical and clinical studies. 
Threshold criteria (Go/No-Go) can be set. 
Shortcomings include: limited sensitivity; variations in oocyst numbers between experiments; limited number of 
suitable cultured parasite strains. There is uncertainty about the relative importance of: percentage of 
individuals rendered non-infectious; percentage of mosquitoes rendered non-infectious after feeding; reduction 
of parasite numbers, and the relation between any of these measures and effects on transmission at population 
level. 
Greater standardization is under investigation.  The suggested output is a control/test ratio for each test to 
minimize effects of variability. 
4 Non-clinical assays using transgenic rodent malaria parasites that express P. falciparum sexual 
stage genes[17]. 
Figure 2 Assays for evaluation of reduction in transmission from humans to mosquitoes. A priority is for assays with acceptable precision
to improve comparability between trials and to assist regulatory authorities.
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on transmission (TBV). Cluster randomized trials can be
used for any VIMT, measuring both the direct and indir-
ect effects, as well as for TBV. Contamination amongst
clusters is a problem and a 2-4 km buffer zone was
recommended during a MALVAC consultation.
Surrogate endpoints for assessing transmission-blocking
vaccines in humans were proposed [16] using e g. oocyst
prevalence in membrane feeding. Whether conducted pre-
or post-licensure (i.e. Phase III or Phase IV), trials desig-
ned to evaluate the effect of a TBV on transmission will be
necessary and could incorporate the surrogates or bio-
markers as additional endpoints. The primary endpoint
for a Phase III trial of a TBV would be incidence of human
infection, and sensitive assays for detection of infection
are necessary for such a purpose. Secondary endpoints
may include incidence of clinical cases and entomological
measures such as EIR, although it should be noted that in
trial settings, transmission might be close to the lowest
transmission level at which EIR measurements are reliable.
Tertiary endpoints derived from serological or nucleic
assay measures become important for surveillance–related
operational research.
Age groups should always include children through to
adolescents, but further research and modelling on the
distribution of the infectious reservoir will be required
to determine whether this needs to be extended to
young adults or even the whole population (except
groups who could be at high risk of vaccine side-effects).
A follow-up of at least two years is required.
Transmission-blocking vaccine development
Good progress has been made using different approaches
to development of transmission-blocking vaccines that tar-
get sexual or sporogonic stages of the life cycle. Candidate
vaccines expressing antigens of P. falciparum involved in
fertilization induced strong transmission-blocking activity
assessed with standard membrane feeding assays [18]. Vari-
ous vaccine formulations of a post-fertilization molecule
had equally high transmission-blocking activity [19,20].
Conjugates have been developed for phase I trials and
formulation of vaccines to further enhance their immuno-
genicity is under investigation. Combination vaccines with
pre-erythrocytic and sexual stage components are planned.
Preferred product characteristics require further work.
Modelling impact of anti-malarial interventions
Leading modelling groups combined to present opinions
on the questions relating to impact of interventions that
are best answered by modelling, the outcomes of par-
ticular interest to show impact on transmission, and
what field data are necessary to make models more
robust [16]. It was strongly recommended that field
researchers work with modelling groups to improve out-
puts as the models need more information on:
 different levels and heterogeneity of transmission;
 the influence of superinfection on duration of
infection and infectivity;
 the infectious reservoir and age structure in low
transmission settings;
 the rate of acquisition of immunity in different
transmission settings and loss of immunity when
transmission is reduced;
 vector species and densities;
 the relationship between transmission and climate;
 human behaviour and socio-economic factors.
There is a large discrepancy between estimates of Ro in
high transmission settings measured by the number of in-
fections per person per unit of time-the force of infection
(FOI), or by the entomological inoculation rate (EIR). The
effect of a TBV can be measured by the proportionate re-
duction in probability that a mosquito acquires infection
at a given feed. Prevalence of infection in mosquitoes is
probably more important than density of infection.
Specific TBV may not be better at interrupting trans-
mission than other vaccines, all of which could have the
additional benefit of an indirect effect on transmission.
However, chances of elimination depend on coverage,
initial transmission level, good surveillance, natural im-
munity and human population size. Vaccines need con-
sideration in terms of both transient dynamics and
effects over time. Transmission is heterogeneous with
respect to intensity, seasonality, vector species and foci
of infections. Modelling should be able to accommodate
this heterogeneity together with human infectiousness
and immunity in order to inform discussions about who
and when to vaccinate with a transmission-blocking
vaccine and which other interventions should be in-
cluded [21]. Sensitivity analyses are important to provide
information on key parameters driving uncertainty in
the models. Further transmission-related epidemiological
studies may be very helpful for data fitting, depending
on the study design.
Whole organism malaria vaccines
Attenuated sporozoite vaccines
Humans exposed to bites of large numbers of infected
irradiated mosquitoes have shown a high level of short-
term protection in controlled human malaria infection
trials [22-25]. This has provided a basis for research into
the development of attenuated sporozoite vaccines. An
irradiated sporozoite production programme using GMP
procedures has been developed and has made available
clinical grade materials for phase I/IIa vaccine trials [26].
Proof of concept studies have begun in adults with
radiation-attenuated vaccines [27].
Considerations that require evaluation and further
research include the size of the vaccine dose, the
Targett et al. Malaria Journal 2013, 12:362 Page 7 of 11
http://www.malariajournal.com/content/12/1/362
number of doses and their timing, routes of adminis-
tration, longevity of protection, boosting, immune
correlates of protection, protection against heterol-
ogous challenge, and storage, stability and transport
of the vaccines. Genetically-attenuated sporozoites po-
tentially provide an alternative to irradiated sporozo-
ites as vaccines but the possibility of reversion to
virulence or under-attenuation with both irradiated
and genetically attenuated sporozoites requires careful
assessment [28].
Sporozoite inoculation and chemoprophylaxis
Volunteers exposed to bites of mosquitoes infected with
P. falciparum while simultaneously given chloroquine
prophylaxis were fully protected against a challenge in-
fection given 2.5 years later opening a new approach to
studies on mechanisms of pre-erythrocytic protective
immunity [29].
Asexual blood stage whole organism vaccines
Low dose parasitized erythrocyte inoculation, leading to
infection controlled by chemotherapy, can provide pro-
tection against challenge infections in malaria naive vol-
unteers without induction of detectable antibody [22,30].
A key safety requirement is a constant source of erythro-
cytes and other blood products free from adventitious
agents. The antigenicity of infected red blood cells in
vaccinated volunteers needs to be ascertained but has
not been a problem so far. This system of “experimental
medicine” can provide insights into protective immune re-
sponses induced, and antigenic correlates of protection to
guide later production of defined antigen vaccines, even if
the concept does not progress as a candidate vaccine in its
own right. Issues identified for further studies include
whether antibody in malaria-exposed individuals would
interfere with the vaccine and whether adjuvants are re-
quired to help promote the desired immune response.
Plasmodium vivax vaccine-related research
Much of the vaccine-related research and planning is
focussed on P. falciparum malaria yet the burden of dis-
ease due to P. vivax is high. The global population at
risk of P. vivax has been estimated at over 2 billion [31].
Outside Africa, P. vivax accounts for more than 50 per
cent of malaria cases. There are wide uncertainty ranges
around global disease burden estimates for P. vivax,
although it is agreed that P. vivax represents a major
cause of disease in Asia and South America in particular.
There is increasing evidence for P. vivax infection in
more settings in Africa [32].
Two WHO MALVAC meetings considered priorities
in research and development of vaccines against P. vivax
[33] and provided detailed guidance on the evaluation of
P. vivax vaccines in naturally exposed populations [34].
Research required for development of vaccines against
vivax malaria
Plasmodium vivax has aspects of its biology and life cycle
that are species-specific when compared with P. falciparum
and these make all control measures more difficult: in-
fectious gametocytes appear early in the infection; de-
velopment in the liver includes formation of persisting
hypnozoites; the extrinsic cycle is shorter and is completed
at a lower temperature; there is efficient transmission even
when mosquitoes are highly seasonal. Plasmodium vivax
and P. falciparum are commonly sympatric, particularly
where transmission of P. vivax is high. There is conflicting
evidence on the impact of one species on the other.
Detailed baseline studies that are required include: bur-
den of disease; the clinical spectrum and incidence of
severe malaria and mortality; relapse patterns; strain hetero-
geneity; interactions with other species and seasonality of P.
vivax and P. falciparum; immunology specific to P. vivax
and in mixed infections; economic analyses. These will
guide determination of sample size in trials, timing of vac-
cination, and surveys in relation to transmission.
Data are required particularly on sensitivity to drugs
needed for radical treatment, especially to primaquine, and
on the rate of G6PD deficiency. No radical cure treatment
is fully effective. Though pre-erythrocytic and asexual
blood-stage vaccines are needed, special consideration of
the role of vaccines in blocking transmission is required. In
the long-term quest for eradication, the MalERA consult-
ation [35] acknowledged that further basic research to
achieve this goal must include as priorities continuous
in vitro culture of asexual blood stage forms and gameto-
cytes, and hypnozoite production in relevant cell lines.
Non-human models of P. vivax are available, but these
match human infections in variable ways and should, there-
fore, be chosen according to the questions being asked.
Clinical trials
Plasmodium vivax presents some substantial additional
challenges when compared with P. falciparum; these are
highlighted below. It is noted that testing for protection
against hypnozoites is currently not possible.
Controlled human malaria infection trials
Like P. falciparum, a standardized human sporozoite chal-
lenge model is required for evaluation of pre-erythrocytic
vaccine candidates. However, it is not yet possible to chal-
lenge with the same highly characterized clone of P. vivax
due to the lack of continuous asexual and gametocyte
in vitro culture systems. Challenges have been conducted
with varying numbers (3–9) of mosquitoes infected with dif-
ferent P. vivax strains. Challenge studies thus include the
additional issues of challenge with wild type parasites and
the possibility of relapses. There are plans to produce
vialled, cryopreserved P. vivax sporozoites for a needle-
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based P. vivax challenge model (cf P. falciparum). As with
P. falciparum, Phase IIa trials are helpful for pre-
erythrocytic vaccines, but somewhat contentious for blood-
stage vaccine candidates.
Phase IIb and Phase III trial designs for Plasmodium vivax
The sequence of trials required is similar to that for
P. falciparum. With P. vivax, vaccine profiles are based
on the need to identify the target groups:
(i) to prevent infection in all age groups in low endemic
areas. Mass vaccination may be aimed at elimination
or outbreak control.
(ii) to prevent disease in infants and children in high
transmission areas – where P. vivax and
P. falciparum infections are commonly co-endemic.
(iii) to vaccinate migrants, who need long-term
protection to cover relapses.
Initial Phase IIb/III trials should be in highly endemic
areas (in children under five years of age). Later trials need
to include additional target groups, according to the en-
demicity of infection. Major challenges to study design
and sample size calculations include individuals who have
asymptomatic parasitaemia, hypnozoite infections, and
P. falciparum co-infections that require treatment. Virtu-
ally nothing is known about immunity to hypnozoites and
assessment of their presence is currently not possible;
meaning that production of a highly desirable therapeutic
vaccine is so far out of reach.
For pre-erythrocytic vaccines, a treatment-reinfection de-
sign (involving radical treatment to remove hypnozoites) is
best if the primary endpoint is incidence of infections. It is
difficult to detect mixed infections without molecular tech-
niques. Radical cure to eliminate hypnozoites does however
present problems (e.g. haemolytic effects, compliance, and
not being fully effective). For blood stage vaccines radical
cure is not required if the vaccine will protect equally well
against relapse infections.
Plasmodium vivax efficacy endpoints and follow-up
It is proposed that, for first pre-erythrocytic vaccine trials,
incidence of infection is the primary endpoint required. For
subsequent trials, incidence of disease should be deter-
mined. For blood stage vaccines, the primary efficacy end-
point needed is the incidence of uncomplicated P. vivax.
Particular complications of assessment of P. vivax
trials and follow-up include:
 Genetic diversity of isolates
 Co-infection with P. falciparum and the need to
treat this infection if it becomes symptomatic
 Assessment of efficacy against relapse infections and
the consequent need for long-term follow-up
Conclusions
WHO has played a major convening role in the past three
decades in establishing a normative framework for critical
aspects of vaccine development as antigenically-defined
subunit vaccines, novel platforms and new adjuvants were
introduced for human use, often for the first time in asso-
ciation with malaria vaccine studies. The importance of
early and close involvement of scientists, developers, regu-
lators, and public health physicians has enabled continu-
ing close cooperation in later stages as developers evaluate
vaccines in ways which will enable technical advisory bod-
ies of WHO to have access to the data that will enable
them to provide guidance for country programmes.
This review has focussed on the contributions to clin-
ical trial design. In many cases, the discipline has moved
from theory to practice, with large numbers of trials of
pre-erythrocytic and asexual stage antigens with differ-
ent adjuvants now completed and published, so that new
protocols can benefit from practical experience added to
theoretical considerations. The context has also changed
with many trial sites having experienced gratifying re-
duction in morbidity and mortality, one consequence be-
ing the requirements for larger multi-centre studies and
complications of interpretation from sites with different
intensities of transmission. The reduced transmission
has also caused many to focus mainly on the possible
contribution of vaccines directed against any stages to
reduction of transmission and possible elimination of
malaria. Non-falciparum species have taken a backseat role
at this stage and ongoing debate continues about the best
way of reporting efficacy data. As much is now known and
published on pre-erythrocytic and asexual stage vaccine tri-
als, at least to proof of concept stage (probably better de-
scribed as experimental medicine rather than product
development), the review has given greater attention to
what lies ahead. The focus is on design of trials for which
there is little or no experience, namely trials of vaccines for
P. vivax, and trials for assessment of reduction of transmis-
sion, and for which preferred product characteristics are
still the subject of debate (for example with respect to effi-
cacy against hypnozoites or go/no go criteria for transmis-
sion blocking studies).
The field is forever changing, with falling transmission
leading to changed populations at risk, including older
children beyond the age of the EPI schedule or migrants
at risk of epidemic malaria. Vaccines that could be used
locally for control or elimination of multi-drug resistant
malaria require consideration of new product profiles
and novel ways of assessing combined efforts with mul-
tiple tools for malaria control that call for better ways of
measuring effects when transmission is low and non-
uniformly distributed.
The review has highlighted the past and ongoing con-
tribution made by WHO in convening groups to address
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key issues for investigators, vaccine developers, regula-
tory authorities and funders in ensuring the most effi-
cient use of resources for developing much-needed
vaccines for use in malaria endemic countries.
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